Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: ARDS, ARDS Disease Progression. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Spain
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Longitudinal Recovery Trajectories After an Acute Respiratory Distress Syndrome, a New Understanding. The TENACITY Study
Overview
COVID-19 resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the respiratory sequelae after an acute distress respiratory syndrome (ADRS). Despite the advancement of acute-phase ARDS management, it is unknown whether there are differences in the longitudinal recovery trajectories between patients with post-ARDS due to COVID-19 and due to other causes. The main objective of the study is to identify risk factors of pulmonary sequela (lung diffusing capacity) at long-term follow-up in survivors of ARDS. The investigators are also interested in describing the long-term longitudinal recovery trajectories at a multi-dimensional level (symptoms, quality of life, neurocognitive, other lung function parameters, exercise capacity, chest imaging and molecular profiles) of ARDS survivors, and compared between ARDS caused by COVID-19. The ultimate goal is to understand the pathobiological mechanisms associated with a severe lung injury at the long term, allowing the introduction of clinical guidelines for the management of post-ARDS patients and the assignment of personalized interventions.
Detailed description
The coronavirus disease 2019 (COVID-19) resulted in the largest cohort of critical illness survivors in history, heightened awareness of the importance of the multi-dimensional sequelae after an acute distress respiratory syndrome (ADRS). With the advancement of acute-phase ARDS management, it is unknown whether there are differences in longitudinal recovery trajectories in terms of lung function, symptoms, quality of life, neurocognitive disorders, exercise capacity, chest imaging, and even at molecular basis between patients with post-ARDS due to COVID-19 and due to other causes. This project will continue to generate information about non-COVID-19 post-ARDS based on the experience in our post-COVID consultation that began in May 2020.
The main objective of the study is to identify risk factors of pulmonary sequela in terms of DLCO at long-term follow-up in survivors of ARDS. The investigators are also interested in describing the long-term longitudinal recovery trajectories at a multidimensional level (symptoms, quality of life, neurocognitive, other lung function parameters, exercise capacity, chest imaging and molecular profiles) of ARDS survivors. Furthermore, risk factors as well as recovery trajectories will be compared between ARDS caused by COVID-19 and non-COVID-19. The ultimate goal is to understand the pathobiological mechanisms associated with a severe lung injury at the long term (one year after hospital discharge), in order to provide novel therapeutic targets to develop future intervention studies.
For doing so, adult ARDS survivors of any origin (different than COVID-19) (n=246) referred to the post-CRITICAL consultation at the University Hospitals of Arnau de Vilanova and Santa Maria (Lleida), University Hospital Joan XXIII (Tarragona) and Verge de la Cinta (Tortosa) will be included in this multicentric, prospective, longitudinal and observational study. Previous standardized protocol will be followed at 3, 6 and 12 months after hospital discharge with a complete evaluation of symptoms, neurocognitive, memory problems and quality of life. Lung function, exercise test, chest CT and molecular analysis will be performed at each time point. The prognostic factors and the longitudinal recovery trajectories of ARDS survivors will be assessed using latent class mixed and machine learning artificial models.
The specific objectives to achieve the general objective are the following:
* Objective 1: To identify risk factors of lung function sequelae (spirometry, total lung volumes and lung diffusing capacity) in non-COVID-19 ARDS survivors. * Objective 2: To identify risk factors of structural pulmonary sequelae (chest CT findings) in non-COVID-19 ARDS survivors. * Objective 3: To identify risk factors of symptoms, neurocognitive disorders (BC-CCI, MOCA) and quality of life (SF-12) in non-COVID-19 ARDS survivors. * Objective 4: To develop a clinical scoring tool to predict pulmonary sequelae at short- and long-term follow-up. * Objective 5: To compare risk factors and recovery trajectories with COVID-19 ARDS survivors using data previously collected. * Objective 6: To use artificial intelligence to identify multidimensional phenotypes associated with recovery trajectories. * Objective 7: To design a cost-effective follow-up plan after hospital discharge in ARDS patients based on hospital risk factors. * Objective 8: To identify molecular profiles according to recovery trajectories in non-COVID-19 ARDS.
Primary outcome measures
- Changes in lung diffusing capacity [Time frame: 3, 6 and 12 months]
- Changes in lung diffusing capacity [Time frame: 3, 6 and 12 months]
- Changes in lung volumes [Time frame: 3, 6 and 12 months]
- Changes in lung volumes [Time frame: 3, 6 and 12 months]
- Changes in chest CT findings [Time frame: 3, 6 and 12 months]
Secondary outcome measures (12)
- Changes in the perceived cognitive difficulties [Time frame: 3, 6 and 12 months]
- Changes in the cognitive function [Time frame: 3, 6 and 12 months]
- Changes in the fatigue status [Time frame: 3, 6 and 12 months]
- Changes in the levels of anxiety [Time frame: 3, 6 and 12 months]
- Changes in independence to carry out daily activities [Time frame: 3, 6 and 12 months]
- Changes in the perception of life quality [Time frame: 3, 6 and 12 months]
- Validation of a clinical scoring tool [Time frame: 3, 6 and 12 months]
- Cost-effectiveness of a follow-up plan [Time frame: 3, 6 and 12 months]
- Identification of molecular profiles [Time frame: 3, 6 and 12 months]
- Multidimensional phenotypes [Time frame: 3, 6 and 12 months]
- Recovery trajectories of lung diffusing capacity [Time frame: 3, 6 and 12 months]
- Recovery trajectories of total lung capacity [Time frame: 3, 6 and 12 months]
Eligibility criteria
Inclusion criteria
- Male and female patients aged ≥18 years
- Admission to the ICU
- Diagnosis of severe pneumonia and/or diagnosis of acute respiratory distress syndrome (ARDS) based on the 2023 definition due to any origin (infectious and non-infectious)
Exclusion criteria
- Life expectancy less than a year
- Transfer to another hospital during hospitalization or follow-up
- Stay in palliative care
- Severe mental disability that makes it impossible to carry out pulmonary function tests during follow-up
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Spain · 3 centers
- Hospital de Tortosa Verge de la Cinta — Tortosa
- Hospital Universitari Arnau de Vilanova — Lleida
- Hospital Universitari Joan XXIII — Tarragona
Identifiers
NCT: NCT06083363 · PI23/01381